Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Travere Therapeutics和CSL Vifor宣布,欧洲药品管理局的CHMP已建议批准Sparsentan用于尿蛋白排泄量>1.0克的原发性IgA肾病;预计欧盟委员会将在2024年第二季度做出决定